DE60327925D1 - Verwendung von löslichem fgl2 als immunosuppressivum - Google Patents
Verwendung von löslichem fgl2 als immunosuppressivumInfo
- Publication number
- DE60327925D1 DE60327925D1 DE60327925T DE60327925T DE60327925D1 DE 60327925 D1 DE60327925 D1 DE 60327925D1 DE 60327925 T DE60327925 T DE 60327925T DE 60327925 T DE60327925 T DE 60327925T DE 60327925 D1 DE60327925 D1 DE 60327925D1
- Authority
- DE
- Germany
- Prior art keywords
- soluble fgl2
- immunosup
- pressive
- methods
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100038647 Fibroleukin Human genes 0.000 title 1
- 101001031613 Homo sapiens Fibroleukin Proteins 0.000 title 1
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36105602P | 2002-03-01 | 2002-03-01 | |
| PCT/CA2003/000273 WO2003074068A2 (en) | 2002-03-01 | 2003-02-28 | Use of soluble fgl2 as an immunosuppressant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60327925D1 true DE60327925D1 (de) | 2009-07-23 |
Family
ID=27789065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60327925T Expired - Lifetime DE60327925D1 (de) | 2002-03-01 | 2003-02-28 | Verwendung von löslichem fgl2 als immunosuppressivum |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7632495B2 (de) |
| EP (1) | EP1482961B1 (de) |
| AT (1) | ATE433326T1 (de) |
| AU (1) | AU2003208197A1 (de) |
| CA (1) | CA2477312C (de) |
| DE (1) | DE60327925D1 (de) |
| WO (1) | WO2003074068A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| CA2682429A1 (en) * | 2009-05-20 | 2010-11-20 | Gary Levy | An assay for measuring plasma fgl-2 and methods and uses thereof |
| US9005630B2 (en) * | 2012-11-01 | 2015-04-14 | Veterinaerinstituttet | Fusion proteins for the treatment of allergic diseases |
| AU2013340899B2 (en) * | 2012-11-01 | 2017-10-05 | Veterinaerinstituttet | New fusion proteins for the treatment of allergic diseases |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| CA3172608A1 (en) * | 2020-03-31 | 2021-10-07 | Ilana MANDEL | Immunosuppressing compositions comprising a fibrinigen-related domain from fibrinogen-like protein 2 and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| CA2289979C (en) * | 1997-05-15 | 2007-02-20 | Transplantation Technologies Inc. | Methods of modulating immune coagulation |
| WO2003066848A1 (en) * | 2002-02-07 | 2003-08-14 | Trillium Therapeutics Inc. | Porcine fgl2 |
-
2003
- 2003-02-28 AT AT03706150T patent/ATE433326T1/de not_active IP Right Cessation
- 2003-02-28 US US10/504,328 patent/US7632495B2/en not_active Expired - Lifetime
- 2003-02-28 DE DE60327925T patent/DE60327925D1/de not_active Expired - Lifetime
- 2003-02-28 AU AU2003208197A patent/AU2003208197A1/en not_active Abandoned
- 2003-02-28 WO PCT/CA2003/000273 patent/WO2003074068A2/en not_active Application Discontinuation
- 2003-02-28 CA CA2477312A patent/CA2477312C/en not_active Expired - Fee Related
- 2003-02-28 EP EP03706150A patent/EP1482961B1/de not_active Expired - Lifetime
-
2009
- 2009-11-03 US US12/611,496 patent/US20100048486A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7632495B2 (en) | 2009-12-15 |
| EP1482961A2 (de) | 2004-12-08 |
| WO2003074068A3 (en) | 2003-12-18 |
| EP1482961B1 (de) | 2009-06-10 |
| ATE433326T1 (de) | 2009-06-15 |
| CA2477312A1 (en) | 2003-09-12 |
| US20100048486A1 (en) | 2010-02-25 |
| WO2003074068A2 (en) | 2003-09-12 |
| US20050164923A1 (en) | 2005-07-28 |
| CA2477312C (en) | 2013-02-26 |
| AU2003208197A8 (en) | 2003-09-16 |
| AU2003208197A1 (en) | 2003-09-16 |
| HK1071079A1 (en) | 2005-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0312331A2 (pt) | composições de ácido hialurônico e métodos de emprego. | |
| DK1032662T3 (da) | Fremgangsmåder og sammensætninger til immunmodulation | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
| BRPI0507118A (pt) | polipeptìdeos de interferon humano modificado e seus usos | |
| ATE304592T1 (de) | Automatisierung im proteinentwurf durch proteinbibliotheken | |
| ATE251942T1 (de) | Stapelbare statische mischelemente | |
| WO2004001019A3 (en) | Novel nanoparticles and use thereof | |
| WO2004084805A3 (en) | Acetylated tat polypeptides and methods of use thereof | |
| DK1448229T3 (da) | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr | |
| SI1644484T1 (sl) | Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah | |
| EA200602137A1 (ru) | Гидрогелевые препараты интерферона | |
| ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
| WO2001068697A3 (en) | Methods and compositions for immunoregulation | |
| ATE484201T1 (de) | Verwendung von beta-cryptoxanthin | |
| PT1276763E (pt) | Proteinas anti-congelantes sua producao e utilizacao | |
| DE60327925D1 (de) | Verwendung von löslichem fgl2 als immunosuppressivum | |
| WO2005009366A3 (en) | Restoring vascular function | |
| DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
| DE50009838D1 (de) | Humanes antibiotisches protein | |
| DE69839943D1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
| DK1444356T3 (da) | Identifikation af epitoper og mindskelse af allergeniciteten af fødevareproteiner | |
| DE60134408D1 (de) | Für akzessorische hiv proteine kodierende dna impfstoffe | |
| TR201900241T4 (tr) | Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar. | |
| ATE370964T1 (de) | Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| R081 | Change of applicant/patentee |
Ref document number: 1482961 Country of ref document: EP Owner name: VERITAS THERAPEUTICS INC., CA Free format text: FORMER OWNER: GARY LEVY, THORNHILL, CA Effective date: 20110620 |
|
| R082 | Change of representative |
Ref document number: 1482961 Country of ref document: EP Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU |